A Phase 3 interventional study of NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine and Prototype/XBB.1.5 Bivalent Vaccine (5 µg) in COVID-19, sponsored by Novavax. Completed at 20 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-15.
Sponsored by Novavax · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in COVID-19 by Novavax — none open to participants now, none under way, none of them phase 3. COVID-19 · Novavax.
Among the 21 studies in COVID-19 by Novavax, this one is the 15th largest by enrollment, is one of 4 that started in 2023, is one of 8 in phase 3, and was the 15th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →None of the 21 studies in COVID-19 by Novavax is open now. The open studies under COVID-19, anywhere →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 11 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 2
First in 2020; this study’s year is marked. 4 started in 2023.
This study's enrollment of 400 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 911 across the 21 interventional studies. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novavax is the lead sponsor of 47 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in COVID-19 by Novavax, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5. The main focus is on safety: researchers want to see if this new booster is safe for teenagers who have already received two doses of the Pfizer or Moderna mRNA COVID-19 vaccines. To ensure a fair comparison, the study will use a double-blind approach. This means two groups of teenagers will receive booster shots, but neither the teenagers nor the researchers giving the shots will know beforehand which version of the booster each person gets. The study will also assess how well the body fights the virus after the booster shot.
This is a Phase 3, randomized, double-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccines (SARS-CoV-2 rS) adjuvanted with Matrix-M™ adjuvant (NVX-CoV2601 [Omicron XBB.1.5]) and bivalent (NVX-CoV2373 [prototype] + NVX CoV2601) in previously vaccinated adolescent participants ≥ 12 to \< 18 years of age.
Approximately 400 adolescents who have received a regimen of ≥ 2 doses of the Moderna and/or Pfizer-BioNTech monovalent and/or bivalent COVID-19 vaccines ≥ 90 days previously will be randomized 1:1 to Group A or Group B:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chronic administration (defined as > 14 continuous days) of , systemic , or other immune-modifying drugs within 90 days prior to study vaccination.
An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical or intranasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Monovalent NVX-CoV2601 of 5 μg of antigen with 50 μg of Matrix-M adjuvant
Biological: NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine
The Bivalent NVX CoV2373 + NVX CoV2601 of 5 μg of each antigen with a total of 50 μg of Matrix-M adjuvant
Biological: Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
Coformulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine with Matrix-M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg antigen and 100 µg adjuvant per mL. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg Matrix-M adjuvant.
Also known as: NVX-CoV2601
A site-mixed bivalent vaccine prepared by combining 0.25 mL of NVX-CoV2373 and 0.25 mL NVX-CoV2601. All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 50 µg Matrix-M adjuvant.
Also known as: Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant
Participants With Solicited Local and Systemic AEs for 7 Days Following Vaccination
Participants with solicited local and systemic adverse events (AEs) To assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) for 7 days following vaccination
Time frame: Day 7
Participants With Unsolicited AEs Through 28 Days After Vaccination
Participants with unsolicited AEs to assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) through 28 days after vaccination.
Time frame: Day 28
Participants With (MAAEs) Attributed to Study Vaccine, (AESIs) (PIMMCs), Myocarditis and/or Pericarditis, and Complications Specific to COVID-19), and Serious Adverse Events (SAEs)
Participants with medically attended adverse events (MAAEs) attributed to study vaccine, adverse events of special interest (AESIs) (predefined list including potential immune-mediated medical conditions (PIMMCs), myocarditis and/or pericarditis, and complications specific to COVID-19), and serious adverse events (SAEs) o assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601)through day 180 or end of study (EOS).
Time frame: Day 180
Immunogenicity Index- Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.
The neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain assessed at Day 28 following initial study vaccination.
Time frame: Day 0 and Day 28
Immunogenicity Index- The Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.
the neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain, assessed at Day 28
Time frame: Day 28
Neutralizing Antibody (NAb) Expressed as Geometric Mean Titers (GMTs) to the Omicron XBB.1.5 Strain.
the neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.
Time frame: Day 0 to Day 180
Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain.
The neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.
Time frame: Day 28 to Day 180
IgG Geometric Mean ELISA (Enzyme-linked Immunosorbent Assay) Units (GMEUs) to the Omicron XBB.1.5 S Protein.
The immunoglobulin G (IgG) antibody levels induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time.at relevant time points.
Time frame: Day 0 to Day 180
NAb(Neutralizing Antibody Titers) Levels Are Measured to the Ancestral (Wuhan) Strain .
The NAb antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points .
Time frame: Day 0 to 180
Serum IgG GMEUs Levels Are Measured to the Ancestral (Wuhan) Strain .
The serum IgG antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points.
Time frame: Day 0 to Day 180
| Milestone | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Started | 190 | 210 |
| Completed | 187 | 201 |
| Not completed | 3 | 9 |
| Withdrew: Early termination | 3 | 9 |
Participants with solicited local and systemic adverse events (AEs) To assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) for 7 days following vaccination
| participants | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Any Solicited AEs | 153 | 166 |
| Local AEs | 136 | 140 |
| Systemic AEs | 116 | 120 |
Participants with unsolicited AEs to assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) through 28 days after vaccination.
| participants | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Any unsolicited TEAE through 28 days after study vaccination | 25 | 25 |
| Infections and infestations | 15 | 13 |
| Psychiatric disorders | 4 | 2 |
| General disorders and administration site conditions | 3 | 3 |
| Respiratory, thoracic and mediastinal disorders | 2 | 3 |
| Gastrointestinal disorders | 3 | 1 |
| Skin and subcutaneous tissue disorders | 2 | 1 |
| Injury, poisoning and procedural complications | 2 | 0 |
| Blood and lymphatic system disorders | 1 | 1 |
| Musculoskeletal and connective tissue disorders | 1 | 1 |
| Nervous system disorders | 0 | 1 |
| Metabolism and nutrition disorders | 0 | 1 |
Participants with medically attended adverse events (MAAEs) attributed to study vaccine, adverse events of special interest (AESIs) (predefined list including potential immune-mediated medical conditions (PIMMCs), myocarditis and/or pericarditis, and complications specific to COVID-19), and serious adverse events (SAEs) o assess the overall safety of 1 heterologous booster dose of NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601)through day 180 or end of study (EOS).
| participants | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Any TEAEs | 25 | 25 |
| Any MAAEs | 16 | 12 |
| Any Serious TEAEs | 4 | 1 |
The neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain assessed at Day 28 following initial study vaccination.
| geometric mean titer | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Day 0 | 208.40 (166.20 to 261.32) | 184.81 (148.86 to 229.45) |
| Day 28 | 2533.08 (2107.17 to 3045.07) | 1544.61 (1314.33 to 1815.25) |
the neutralizing antibody (NAb) response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain, assessed at Day 28
| geometric mean fold rise | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Immunogenicity Index- The Neutralizing Antibody (NAb) Expressed as Geometric Mean Fold Rise (GMFR) to the Omicron XBB.1.5 Strain. | 12.2 (9.5 to 15.5) | 8.4 (6.8 to 10.3) |
the neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.
| geometric mean titer | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Day 0 | 204.98 (163.68 to 256.69) | 183.37 (147.82 to 227.47) |
| Day 28 | 2533.08 (2107.17 to 3045.07) | 1544.61 (1314.33 to 1815.25) |
| Day 90 | 1816.50 (1505.62 to 2191.56) | 1171.90 (997.69 to 1376.52) |
| Day 180 | 1369.61 (1128.29 to 1662.53) | 866.10 (733.49 to 1022.67) |
The neutralizing antibody NAb response induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time. at relevant time points.
| geometric mean fold rise | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Day 28 | 12.2 (9.5 to 15.5) | 8.4 (6.8 to 10.3) |
| Day 90 | 8.6 (6.7 to 11.1) | 6.2 (5.0 to 7.7) |
| Day 180 | 6.0 (4.7 to 7.8) | 4.7 (3.7 to 5.9) |
The immunoglobulin G (IgG) antibody levels induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the Omicron XBB.1.5 strain over time.at relevant time points.
| Elisa Units per mL | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Day 0 | 38825.1 (33160.1 to 45457.9) | 32881.9 (28434.7 to 38024.7) |
| Day 28 | 150232.9 (132853.6 to 169885.6) | 113031.9 (101227.0 to 126213.4) |
| Day 90 | 110091.1 (96294.7 to 125864.3) | 87102.4 (77115.6 to 98382.6) |
| Day 180 | 77149.8 (68110.5 to 87388.8) | 61647.7 (55459.2 to 68526.7) |
The NAb antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points .
| geometric mean titer | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Day 0 | 1321.00 (1123.04 to 1553.87) | 1197.59 (1029.90 to 1392.58) |
| Day 28 | 3510.84 (3099.99 to 3976.14) | 2803.80 (2453.96 to 3203.51) |
| Day 90 | 3381.08 (2991.33 to 3821.62) | 2924.82 (2581.96 to 3313.23) |
| Day 180 | 2663.87 (2334.49 to 3039.72) | 2357.51 (2095.11 to 2652.77) |
The serum IgG antibody responses induced by NVX CoV2601 and the bivalent vaccine (NVX CoV2373 + NVX-CoV2601) against the ancestral (Wuhan) strain at relevant time points.
| Elisa Units per mL | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Day 0 | 71388.4 (62262.8 to 81851.6) | 61296.9 (53962.1 to 69628.5) |
| Day 28 | 181736.6 (162092.7 to 203761.1) | 157077.8 (141109.2 to 174853.4) |
| Day 90 | 142032.4 (124824.9 to 161611.9) | 130155.1 (116798.0 to 145039.8) |
| Day 180 | 104890.2 (93135.9 to 118128.0) | 94026.0 (84606.1 to 104494.8) |
Collected over 180 Days. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group-A NVX-CoV2601 | 0/190 (0%) | 7/190 (3.7%) | 10/190 (5.3%) |
| Group-B Bivalent NVX CoV2373 + NVX CoV2601 | 0/210 (0%) | 1/210 (0.5%) | 4/210 (1.9%) |
| Event | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 3/190 | 0/210 |
| Adjustment disorder with anxietyPsychiatric disorders | 1/190 | 0/210 |
| Adjustment disorder with depressed moodPsychiatric disorders | 1/190 | 0/210 |
| DepressionPsychiatric disorders | 1/190 | 0/210 |
| Post-traumatic stress disorderPsychiatric disorders | 1/190 | 0/210 |
| Disruptive mood dysregulation disorderPsychiatric disorders | 0/190 | 1/210 |
| Event | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 10/190 | 4/210 |
| Age, Continuous(years) | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 | Total |
|---|---|---|---|
| Mean | 14.5 ± 1.77 | 14.5 ± 1.65 | 14.5 ± 1.05 |
| Sex: Female, Male(Participants) | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 | Total |
|---|---|---|---|
| Female | 99 | 107 | 206 |
| Male | 91 | 103 | 194 |
| Ethnicity (NIH/OMB)(Participants) | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 | Total |
|---|---|---|---|
| Hispanic or Latino | 43 | 47 | 90 |
| Not Hispanic or Latino | 147 | 163 | 310 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group-A NVX-CoV2601 | Group-B Bivalent NVX CoV2373 + NVX CoV2601 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 2 | 10 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 33 | 44 | 77 |
| White | 137 | 149 | 286 |
| More than one race | 9 | 10 | 19 |
| Unknown or Not Reported | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Apr 2024, 7 months.
Results were first posted in Jul 2025, 1 year 3 months after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.